Moventig® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol), an investigational, peripherally -acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid -induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). OIC is a condition caused by prescription opioid pain medicines. Opioids work by binding to mu-receptors in the central nervous system, but they also bind to mu -receptors in the gastrointestinal tract, which can result in patients suffering from OIC. The positive opinion was reached after a review of comprehensive data from the KODIAC clinical programme comprised of four studies assessing the safety and efficacy of MOVENTIG. The CHMP's positive opinion on MOVENTIG will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. Should the EC approve MOVENTIG, it will be the first once-daily, oral PAMORA available in these markets for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). Today's announcement follows the approval (http://www.astrazeneca.com/Media/Press-releases/Article/20140916--fda -approves-movantik-tablets) on 16 September 2014 of MOVANTIKTM (naloxegol) tablets by the US Food and Drug Administration, as the first once-daily PAMORA for the treatment of OIC in adult patients with chronic non-cancer pain. About MOVENTIG® (naloxegol) MOVENTIG is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) specifically designed for the treatment of opioid-induced constipation (OIC) in adult patients on prescription opioid pain medicines. In Phase III clinical studies, MOVENTIG was administered as a once-daily tablet and was designed to block the binding of opioids to opioid receptors in tissues such as the gastrointestinal (GI) tract. The KODIAC clinical programme was comprised of four studies: KODIAC-4, -5, -7 and -8. KODIAC-4 and -5 were identically designed, placebo controlled, double -blind, 12 week studies assessing safety and efficacy, while KODIAC-7 was a 12 week safety extension to KODIAC-4, and KODIAC-8 was a 52 week long-term safety study. MOVENTIG is part of the exclusive worldwide licence agreement announced on 21 September 2009 between AstraZeneca and Nektar Therapeutics. MOVENTIG was developed using Nektar's oral small molecule polymer conjugate technology. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Investor Enquiries Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Jens Lindberg mob: +44 7557 319729 Anthony Brown +44 20 7604 8067 mob: +44 7585 404943 Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627 26 September 2014 -ENDS-
Positive CHMP Opinion for MOVENTIG (naloxegol) Moventig
Top 10 Most Recent News Articles
CVS Health Under Fire: Fiduciary Duty Breach?
CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...
Continue Reading
AI and Storytelling Make Waves in Science Education
University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...
Continue Reading
Geron Corp Faces Fiduciary Duty Investigation
Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...
Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage
A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...
Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses
The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...
Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices
Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...
Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?
Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....
Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch
PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...
Continue ReadingTop 5 Most Recently Viewed Articles
John B. Sanfilippo & Son Announces Major $1.00 Special Dividend
John B. Sanfilippo & Son Declares Special $1.00 Dividend The management of John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) has exciting news for its shareholders as the company has declared a special cash dividend of $1.00 per share. This amount will be distributed on shares of both Common Stock and Class A Common Stock, which is expected to return about $11.7 million to...
Continue Reading
Recent Disclosure Submission by De La Rue plc Explained
Understanding Recent Disclosure Submissions Corporations frequently engage in the process of disclosing financial information to ensure transparency and compliance with market regulations. Among these, De La Rue plc, a prominent player in the printing and security technology sector, has made an important disclosure pertaining to trades conducted by its exempt principal...
Continue Reading
Perrigo Company Engages Investors at Upcoming Conference
Perrigo Company Engages Investors at Upcoming Conference Dublin - Perrigo Company plc (NYSE: PRGO), renowned for its commitment to consumer health products, has announced that its President and CEO, Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will participate in one-on-one investor meetings at the Jefferies Miami Consumer Conference. This event is set to...
Continue Reading
Hellas Verona Partners with Veronafiere for Chicago Event
Hellas Verona and Veronafiere Collaborate for Vinitaly.USA Hellas Verona Football Club and Veronafiere are excited to announce their latest partnership, aimed at promoting the finest of Italian wines on an international platform. This collaboration emphasizes the upcoming second edition of Vinitaly.USA, a prestigious event highlighting Italian wine in the United States,...
Continue Reading
Bio-Techne to Showcase Innovations at Annual Healthcare Event
Bio-Techne Corporation to Present at Key Healthcare Conference Bio-Techne Corporation (NASDAQ: TECH) is set to take the stage at a prestigious annual healthcare conference. With a focus on innovation and providing indispensable tools for the medical and research communities, Bio-Techne's President and CEO, Kim Kelderman, will share insights on January 14, 2025. This event...
Continue Reading